The U.S. Food and Drug Administration (FDA) has cleared Foundation Medicine's FoundationOne CDx companion diagnostic for identifying patients with microsatellite instability-high (MSI-H) solid tumors who may benefit from Keytruda (pembolizumab) treatment.
Characterizing these tumors helps clinicians identify patients who could benefit from immunotherapy such as Keytruda, a humanized antibody used in cancer immunotherapy, the company said. MSI-H status is a defining feature of colorectal, endometrial, and gastrointestinal cancers.
